PALO ALTO, Calif.–(BUSINESS WIRE)–Science Exchange, the leading marketplace for outsourced R&D™, announces a collaboration with Reveal Biosciences to offer on-demand access to AI-based pathology services worldwide.
Reveal Biosciences is a San Diego-based company that’s leading the next generation of quantitative histopathology, combining the latest artificial intelligence (AI) techniques with high-quality histology, immunohistochemistry (IHC) and in situ hybridization (ISH) to generate enhanced data from tissue samples.
Reveal’s AI-based tissue analysis utilizes trained pathology models to recognize disease patterns in whole slide digital images. This service can be applied to tumor profiling, quantitative immunohistochemistry, NASH, toxicology and quantitative multiplexing. On top of that, Reveal is generating disease-specific AI-based models as pathology decision support tools to accelerate clinical trials for the benefit of patients.
“We are delighted to join forces with Science Exchange,” said Claire Weston, Ph.D., Founder and CEO of Reveal Biosciences. “I am confident that our unique application of artificial intelligence to pathology will benefit Science Exchange’s life sciences community.”
“The use of AI-based tools in pathology is expected to increase significantly over time in both drug discovery and patient diagnostics as it is more cost-effective, accurate, reproducible and scalable,” stated Elizabeth Iorns, Ph.D., co-founder and CEO of Science Exchange. “Reveal Biosciences is the leader in employing an AI-based approach in the pathology space, and we are thrilled to team up with them.”
About Science Exchange
Science Exchange is the world’s leading marketplace for outsourced R&D™, providing large R&D organizations with the fastest path from discovery through development and commercialization. Science Exchange includes an efficient source-to-secure platform for ordering 6,000+ services from a network of more than 2,500 qualified outsourced research providers, all with pre-established contracts in place that protect client intellectual property and confidentiality. The platform increases access to innovation and improves productivity, freeing scientists from administrative tasks and delays associated with sourcing, establishing and managing service provider contracts. Additionally, the Science Exchange enterprise program enables large R&D organizations to consolidate research outsourcing spend into a single strategic relationship, driving efficiency, improving transparency and oversight, and delivering cost savings. Since being founded in 2011, Science Exchange has raised more than $58 million from Norwest Venture Partners, Maverick Capital Ventures, Union Square Ventures, Collaborative Fund, Index Ventures, OATV, the YC Continuity Fund, and others. For more information, visit www.ScienceExchange.com. Follow the company on Twitter @ScienceExchange, Facebook and LinkedIn.
About Reveal Biosciences
Reveal Biosciences is a San Diego-based computational pathology company leveraging artificial intelligence (AI) to enable pathologists to make diagnostic decisions faster, more accurately, and for less money. The company also supports drug development by combining traditional histopathology with AI to transform tissue biology into actionable data. Reveal’s portfolio includes in situ hybridization (ISH), immunohistochemistry (IHC), immunofluorescence (IF), histopathology, and whole slide imaging. Follow the company on Twitter @RevealBio, Instagram @RevealBio, Facebook and LinkedIn.
Contact: Abigail Lim, Marketing Specialist at [email protected]